Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Transplant Infectious Disease

• Publication date

  2016-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/tid.12486PMID 26606757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy And Tolerability of Intravenous Pentamidine Isethionate For Pneumocystis Jiroveci Prophylaxis In A Pediatric Oncology Population

  2014cited by this paper
• Intravenous Pentamidine Is Safe and Effective as Primary Pneumocystis Pneumonia Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation

  2013cited by this paper
• Pneumocystis carinii Pneumonia Prophylaxis

  2011cited by this paper
• Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration

  2011influential reference
• Intermittent oral trimethoprim/sulfamethoxazole on two non‐consecutive days per week is effective as Pneumocystis jiroveci pneumonia prophylaxis in pediatric patients receiving chemotherapy or hematopoietic stem cell transplantation

  2009cited by this paper
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

  2009influential reference
• Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients

  2008cited by this paper
• Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.

  2007cited by this paper
• Successful Intermittent Prophylaxis With Trimethoprim/Sulfamethoxazole 2 Days per Week for Pneumocystis carinii (jiroveci) Pneumonia in Pediatric Oncology Patients

  2007cited by this paper
• Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients

  2006influential reference
• Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study

  2005cited by this paper
• Prevention of Infection Due to Pneumocystis spp. in Human Immunodeficiency Virus-Negative Immunocompromised Patients

  2004cited by this paper
• Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: A strategy for prevention

  2004cited by this paper
• Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia after allogeneic marrow transplantation

  2002influential reference
• Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome.

  2002cited by this paper
• Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: focus on community respiratory virus infections.

  2001cited by this paper
• Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients.

  2001cited by this paper
• Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections.

  2000cited by this paper
• Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients

  2000cited by this paper
• High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis.

  1999cited by this paper
• Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides.

  1999influential reference
• Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group.

  1998cited by this paper
• Prevention of Infection Due to Pneumocystis carinii

  1998influential reference
• Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation.

  1996cited by this paper
• Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk.

  1995cited by this paper
• A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group.

  1995cited by this paper
• Discrimination against people with HIVinfection and AIDS

  1994cited by this paper
• Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole.

  1994cited by this paper
• Pneumocystis carinii pneumonitis following bone marrow transplantation.

  1992cited by this paper
• Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus.

  1992cited by this paper
• [Risk factors and prevention of pneumocystis carinii pneumonia after bone marrow transplantation].

  1992cited by this paper
• Compliance and laboratory data predict relapse rate of pneumocystis carinii pneumonia during prophylaxis with aerosol pentamidine

  1990cited by this paper
• Cardiovascular effects and safety of intravenous and intramuscular pentamidine isethionate.

  1987cited by this paper

• A retrospective study of intravenous pentamidine for PCP prophylaxis in adult patients with hematological malignancies - its utility during respiratory virus pandemics.

  2024cites this paper
• Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list

  2024cites this paper
• Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systematic Review and Meta-Analysis

  2023cites this paper
• Pneumocystis jirovecii Pneumonia Prophylaxis with Intravenous Pentamidine in Adult Allogeneic Hematopoietic Stem Cell Transplant Patients

  2022cites this paper
• Infection Prevention and Prophylaxis

  2021cites this paper
• Effectiveness and tolerability of intravenous pentamidine for Pneumocystis carinii pneumonia prophylaxis in adult hematopoietic stem cell transplant patients: a retrospective study

  2020cites this paper
• [Prophylaxis of infections post-allogeneic transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

  2019cites this paper
• Prevention and Treatment of Other Opportunistic Infections: Nocardiosis, Toxoplasmosis, Chagas and Pneumocystis Disease

  2019cites this paper
• A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant

  2018cites this paper
• Considerations for Medications Commonly Utilized in the Oncology Population in the Intensive Care Unit

  2018cites this paper
• The selective response of a templated polymer for the cationic drug pentamidine: implications from molecular simulations and experimental data

  2017cites this paper
• ATG Based Conditioning Regimen in Stem Cells Transplantation of Fanconi Anemia: A Single Center Experience of 63 Patients

  2017cites this paper
• Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazol for Pneumocystis Jiroveci Prophylaxis in Children With Acute Lymphoblastic Leukemia With a Background of Ethnic Neutropenia

  2017cites this paper
• Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant.

  2016cites this paper